ProSomnus® Listed on the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies

SAN FRANCISCO, August 14, 2025 — ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea OSA) therapy®, announced its inclusion on the prestigious Inc. 5000 list of fastest growing private companies in the USA. This is the fourth year that ProSomnus has earned a spot on the Inc. 5000 list. Persistent and robust … Read more

ProSomnus® Announces Significant Progress on Strategic Programs

SAN FRANCISCO, August 11, 2025 — ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy®, today announced significant progress on strategic programs. The key feature is the successful FDA registration of the company’s HWO2 buccal mucosal wellness oximeter. The ProSomnus HWO2 Device enables patients to monitor their nightly health and wellness … Read more

ProSomnus® Introduces EVO® Guided for the Treatment of Obstructive Sleep Apnea

EVO Guided is the first oral device bioengineered to dilate the oropharynx and the velopharynx SAN FRANCISCO, June 5, 2025 – ProSomnus Sleep Technologies (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy®, announces EVO Guided. EVO Guided is a new precision, custom oral device for the treatment of Obstructive Sleep Apnea (“OSA”). FDA … Read more

Applicant Form

Thank you for your interest in ProSomnus career opportunities. Please choose your department of interest:

Resume Upload

By submitting this form, you may be contacted by our staff to verify information.

Brian Dow

Chief Financial Officer

Brian Dow is the Chief Financial Officer for ProSomnus® Sleep Technologies. Prior to joining ProSomnus in March of 2023, Mr. Dow served as Chief Financial Officer of Agendia N.V., a $60 million molecular diagnostics company, Senior Vice President and Chief Financial Officer of Pulse Biosciences (NASDAQ: PLSE), a development stage medical device company, and Principal Accounting Officer for Pacific Biosciences (NASDAQ: PACB), a commercial stage developer, manufacturer and provider of next generation sequencing instruments. Mr. Dow started his career as a manager with Ernst & Young.

Mr. Dow holds a B.S. in Management from the Georgia Institute of Technology and is recognized as a licensed certified public accountant by the Washington State Board of Accountancy.

Request Your Provider Portal Login Credentials

Please complete the form. A ProSomnus team member will reach out to you with your unique login credentials.

Request an Appointment